Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae
Jayol, AurélieEmerging Antibiotic Resistance Unit, Medical and Molecular, Microbiology, Department of Medicine, University of Fribourg, Switzerland
Nordmann, PatriceEmerging Antibiotic Resistance Unit, Medical and Molecular, Microbiology, Department of Medicine, University of Fribourg, Switzerland - University of Lausanne and University Hospital Center, Lausanne, Switzerland
Poirel, LaurentEmerging Antibiotic Resistance Unit, Medical and Molecular, Microbiology, Department of Medicine, University of Fribourg, Switzerland
Dubois, VéroniqueLaboratory of Bacteriology, University Hospital of Bordeaux, Bordeaux, France - CNRS UMR5234, University of Bordeaux, Bordeaux, France
2017
Published in:
Journal of Antimicrobial Chemotherapy. - 2018, vol. 73, no. 2, p. 542-544
English
The spread of carbapenemase-producing Klebsiella pneumoniae is a major public health concern since such isolates are basically resistant to most available antibiotics, including β-lactams, fluoroquinolones and aminoglycosides.1 Infections due to carbapenemase-producing K. pneumoniae are therefore commonly treated with a regimen containing colistin.1 However, acquired resistance to colistin now occurs frequently and has few therapeutic options.2 Outbreaks with colistin-resistant and carbapenemase-producing K. pneumoniae isolates have been reported worldwide2 and mortality rates are high owing to limited treatment options.3...Recently, a new therapeutic option, namely ceftazidime/avibactam, combining a broad-spectrum cephalosporin and a novel β-lactamase inhibitor, has been marketed. The addition of avibactam expands the spectrum of activity of ceftazidime to many MDR Enterobacteriaceae including producers of ESBLs and carbapenemases.4...